Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Collett

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
Antimicrobial Agents and Chemotherapy|August 15, 2012
Characterization of poliovirus variants selected for resistance to the antiviral compound V-073Hong-Mei Liu, Jason A Roberts, Deborah Moore, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 28, 2000
Mechanism of action of a pestivirus antiviral compoundS G Baginski, D C Pevear, M Seipel, et al.
Current Biology : CB|December 29, 2020
Small and Large Bumblebees Invest Differently when Learning about FlowersElisa Frasnelli, Théo Robert, Pizza Ka Yee Chow, et al.
The Pediatric Infectious Disease Journal|March 10, 2020
Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With PocapavirJulie Copelyn, Jeffrey R Hincks, Jo M Wilmshurst, et al.
Virology|November 17, 2009
Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirusAlexander A Rumyantsev, Zhen-xi Zhang, Qing-sheng Gao, et al.
Virology|July 15, 1985
Complete nucleotide sequence of the M RNA segment of Rift Valley fever virusM S Collett, A F Purchio, K Keegan, et al.
The Journal of Infectious Diseases|October 16, 2014
Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradicationMark A McKinlay, Marc S Collett, Jeffrey R Hincks, et al.
The Journal of Infectious Diseases|December 10, 2016
Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge ModelMarc S Collett, Jeffrey R Hincks, Kimberley Benschop, et al.
The Journal of Infectious Diseases|May 1, 1993
Candidate recombinant vaccine for human B19 parvovirusG P Bansal, J A Hatfield, F E Dunn, et al.
Biochemistry|February 12, 1985
Lysozyme: a major secretory product of a human colon carcinoma cell lineJ W Fett, D J Strydom, R R Lobb, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
Antimicrobial Agents and Chemotherapy|August 15, 2012
Characterization of poliovirus variants selected for resistance to the antiviral compound V-073Hong-Mei Liu, Jason A Roberts, Deborah Moore, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 28, 2000
Mechanism of action of a pestivirus antiviral compoundS G Baginski, D C Pevear, M Seipel, et al.
Current Biology : CB|December 29, 2020
Small and Large Bumblebees Invest Differently when Learning about FlowersElisa Frasnelli, Théo Robert, Pizza Ka Yee Chow, et al.
The Pediatric Infectious Disease Journal|March 10, 2020
Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With PocapavirJulie Copelyn, Jeffrey R Hincks, Jo M Wilmshurst, et al.
Virology|November 17, 2009
Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirusAlexander A Rumyantsev, Zhen-xi Zhang, Qing-sheng Gao, et al.
Virology|July 15, 1985
Complete nucleotide sequence of the M RNA segment of Rift Valley fever virusM S Collett, A F Purchio, K Keegan, et al.
The Journal of Infectious Diseases|October 16, 2014
Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradicationMark A McKinlay, Marc S Collett, Jeffrey R Hincks, et al.
The Journal of Infectious Diseases|December 10, 2016
Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge ModelMarc S Collett, Jeffrey R Hincks, Kimberley Benschop, et al.
The Journal of Infectious Diseases|May 1, 1993
Candidate recombinant vaccine for human B19 parvovirusG P Bansal, J A Hatfield, F E Dunn, et al.
Biochemistry|February 12, 1985
Lysozyme: a major secretory product of a human colon carcinoma cell lineJ W Fett, D J Strydom, R R Lobb, et al.
Pageof 18